These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31919793)

  • 1. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
    Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
    Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
    Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
    Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
    Fishman J; Kim Y; Parisé H; Bercaw E; Smith Z
    J Med Econ; 2024; 27(1):1108-1118. PubMed ID: 39155764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
    Povsic M; Wong OY; Perry R; Bottomley J
    Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.
    Tampi RP; Wong VW; Wong GL; Shu SS; Chan HL; Fung J; Stepanova M; Younossi ZM
    Hepatol Res; 2020 Sep; 50(9):1024-1031. PubMed ID: 32537840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
    O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
    JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.
    Younossi ZM; Tampi R; Priyadarshini M; Nader F; Younossi IM; Racila A
    Hepatology; 2019 Feb; 69(2):564-572. PubMed ID: 30180285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.